Article: Interstitial lung disease associated with anti-PM-Scl antibody: A single center experience
Authors: Kamonpun Ussavarungsi, Kenneth Nugent, Alicia K. Gerke, Matthew D. Krasowski, Rebecca S. Tuetken, Petar S. Lenert
Journal: Autoimmun Rev. 2019 Jul 16:102355. doi: 10.1016/j.autrev.2019.102355. [Epub ahead of print]
Anti-PM-Scl antibody was one of first with nucleolar specificity described as a marker antibody for polymyositis (PM). Due to the low prevalence of anti-PM-Scl antibody, associated clinical features have come from relatively small clinical studies that report its presence in PM, dermatomyositis (DM), or systemic sclerosis (SSc). However, prevalence has been reported to be higher in overlap syndromes of scleroderma with PM or DM, frequently called scleromyositis or sclerodermatomyositis. The prevalence of interstitial lung disease (ILD) in patients with anti-PM-Scl antibody varies from 30 to 86%. We retrospectively reviewed the clinical manifestations, imaging characteristics, and outcomes in patients with ILD associated with anti-PM-Scl antibody (January 2007 through December 2017).
Link to journal online: